{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:17:35Z","timestamp":1788218255570,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.peptides.2019.170174","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T18:13:40Z","timestamp":1572718420000},"page":"170174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-1453","authenticated-orcid":false,"given":"Sebastian M.","family":"Heimb\u00fcrger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha C.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke S.","family":"Gasbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8774-1797","authenticated-orcid":false,"given":"Mikkel B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-5034","authenticated-orcid":false,"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2019.170174_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0196-9781(00)00287-4","article-title":"Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells","volume":"21","author":"Zhong","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2019.170174_bib0015","doi-asserted-by":"crossref","first-page":"E390","DOI":"10.1152\/ajpendo.00509.2002","article-title":"Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1","volume":"285","author":"Ding","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0020","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00507.2003","article-title":"Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. Portal vein endothelial cells","volume":"286","author":"Ding","year":"2004","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0025","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0030","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene","volume":"51","author":"Kim","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.peptides.2019.170174_bib0035","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","article-title":"Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation","volume":"133","author":"Song","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2019.170174_bib0040","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00520.2014","article-title":"Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics","volume":"308","author":"Karstoft","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0045","article-title":"Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2019.170174_bib0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/EC-17-0015","article-title":"Effects of meal and incretins in the regulation of splanchnic blood flow","volume":"6","author":"Koffert","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.peptides.2019.170174_bib0055","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0060","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/oby.2006.129","article-title":"Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification","volume":"14","author":"Getty-Kaushik","year":"2006","journal-title":"Obes. Silver Spring Md"},{"key":"10.1016\/j.peptides.2019.170174_bib0065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000177467","article-title":"Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes","volume":"32","author":"Hauner","year":"1988","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0070","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0075","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0080","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2337\/db16-0758","article-title":"Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high fat diet-fed mice","volume":"66","author":"Joo","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP - A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2019.170174_bib0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1006\/bbrc.2002.6364","article-title":"Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide","volume":"290","author":"Gault","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.peptides.2019.170174_bib0100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2016.1276683","article-title":"Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor","volume":"9","author":"K\u00f6nitzer","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.peptides.2019.170174_bib0105","doi-asserted-by":"crossref","first-page":"19760","DOI":"10.1074\/jbc.M112.426288","article-title":"Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor","volume":"288","author":"Ravn","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0110","first-page":"5","article-title":"A GIP receptor agonist exhibits b-cell anti-apoptotic actions in rat models of diabetes resulting in improved b-cell function and glycemic control","author":"Widenmaier","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2019.170174_bib0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.peptides.2019.170174_bib0120","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00125-007-0692-2","article-title":"Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob\/ob mice","volume":"50","author":"Irwin","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0125","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s00125-007-0710-4","article-title":"Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets","volume":"50","author":"Gault","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0130","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00008.2008","article-title":"Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice","volume":"295","author":"Isken","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1172\/JCI200420518","article-title":"Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors","volume":"113","author":"Preitner","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2019.170174_bib0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors","volume":"289","author":"Mokdad","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.peptides.2019.170174_bib0145","article-title":"GIP-Overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2019.170174_bib0150","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/mnfr.200700048","article-title":"Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome","volume":"51","author":"Nitz","year":"2007","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.peptides.2019.170174_bib0155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.peptides.2019.170174_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng.521","article-title":"Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge","volume":"42","author":"Saxena","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.peptides.2019.170174_bib0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/prot.21372","article-title":"The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy","volume":"68","author":"Ala\u00f1a","year":"2007","journal-title":"Proteins Struct. Funct. Bioinf."},{"key":"10.1016\/j.peptides.2019.170174_bib0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2337\/diab.26.5.480","article-title":"Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat","volume":"26","author":"Taminato","year":"1977","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF01228136","article-title":"Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas","volume":"14","author":"Adrian","year":"1978","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0180","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1210\/jcem-54-5-909","article-title":"The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis","volume":"54","author":"Takemura","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0185","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00125-017-4450-9","article-title":"Enteroendocrine K and L cells in healthy and type 2 diabetic individuals","volume":"61","author":"Jorsal","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0190","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0195","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like Peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.regpep.2006.07.007","article-title":"The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects","volume":"137","author":"Vilsb\u00f8ll","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2019.170174_bib0205","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide","volume":"85","author":"Deacon","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1677\/joe.0.1750525","article-title":"Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo","volume":"175","author":"Gault","year":"2002","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2019.170174_bib0215","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1152\/ajpendo.00577.2005","article-title":"GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations","volume":"291","author":"Deacon","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0220","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2019.170174_bib0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2019.170174_bib0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic b-cells and adipocytes","volume":"3","author":"McIntosh","year":"2012","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.peptides.2019.170174_bib0235","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0240","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/pr.110.003707","article-title":"Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions","volume":"65","author":"Schmidt","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2019.170174_bib0245","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/MCB.00325-07","article-title":"Glucose-Dependent Insulinotropic Polypeptide-Mediated Up-Regulation of beta-Cell Antiapoptotic Bcl-2 Gene Expression Is Coordinated by Cyclic AMP (cAMP) Response Element Binding Protein (CREB) and cAMP-Responsive CREB Coactivator 2","volume":"28","author":"Kim","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.peptides.2019.170174_bib0250","doi-asserted-by":"crossref","first-page":"22297","DOI":"10.1074\/jbc.M500540200","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic \u03b2-Cell survival is dependent upon phosphatidylinositol 3-Kinase (PI3K)\/Protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulat","volume":"280","author":"Kim","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/bbrc.1997.6743","article-title":"Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways","volume":"235","author":"Kubota","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.peptides.2019.170174_bib0260","doi-asserted-by":"crossref","first-page":"23667","DOI":"10.1074\/jbc.M103023200","article-title":"A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion","volume":"276","author":"Ehses","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0265","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2337\/db14-0440","article-title":"Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes","volume":"64","author":"Christensen","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0275","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2019.170174_bib0280","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/db11-1451","article-title":"Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0285","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1001\/jama.2011.1826","article-title":"Temporal changes in resting heart rate and deaths from ischemic heart disease","volume":"306","author":"Nauman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.peptides.2019.170174_bib0290","first-page":"882","article-title":"Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study","volume":"99","author":"Jensen","year":"2013","journal-title":"Heart Br. Card. Soc."},{"key":"10.1016\/j.peptides.2019.170174_bib0295","first-page":"377","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0300","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0310","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14656566.2019.1571040","article-title":"Expert Opinion on Pharmacotherapy the efficacy and safety of exenatide once weekly in patients with type 2 diabetes","volume":"20","author":"Heimb\u00fcrger","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.peptides.2019.170174_bib0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2840-9-17","article-title":"Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease","volume":"9","author":"Yamaoka-Tojo","year":"2010","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.peptides.2019.170174_bib0320","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molmet.2018.05.014","article-title":"The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-\/- mice by blocking monocyte\/macrophage activation","volume":"14","author":"Kahles","year":"2018","journal-title":"Mol. Metab."},{"issue":"38","key":"10.1016\/j.peptides.2019.170174_bib0325","first-page":"259","article-title":"Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects","volume":"2014","author":"Asmar","year":"2005","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2019.170174_bib0330","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1210\/en.2018-00336","article-title":"Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial remodeling in male mice","volume":"159","author":"Mori","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2019.170174_bib0335","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis","volume":"76","author":"Planas-Rigol","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.peptides.2019.170174_bib0340","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2008.03.006","article-title":"Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis","volume":"199","author":"Ivey","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.peptides.2019.170174_bib0345","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) stimulates osteopontin expression in the vasculature via Endothelin-1 and CREB","author":"Berglund","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0350","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cytogfr.2008.08.001","article-title":"Denhardt DT. Osteopontin: role in immune regulation and stress responses","volume":"19","author":"Wang","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.peptides.2019.170174_bib0355","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","article-title":"The role of osteopontin in inflammatory processes","volume":"3","author":"Lund","year":"2009","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.peptides.2019.170174_bib0360","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s003800200005","article-title":"Development of atherosclerosis in osteopontin transgenic mice","volume":"16","author":"Chiba","year":"2002","journal-title":"Heart Vessels"},{"key":"10.1016\/j.peptides.2019.170174_bib0365","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1172\/JCI116755","article-title":"Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques","volume":"92","author":"Giachelli","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2019.170174_bib0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2334\/josnusd.52.221","article-title":"Endothelin-1 regulates rat bone sialoprotein gene transcription","volume":"52","author":"Li","year":"2010","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.peptides.2019.170174_bib0375","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/01.HYP.23.6.1121","article-title":"Nitric oxide synthase isozymes characterization, purification, molecular cloning, and functions","volume":"23","author":"Forstermann","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2019.170174_bib0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035683","article-title":"Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice","volume":"7","author":"Nogi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2019.170174_bib0385","first-page":"54","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.peptides.2019.170174_bib0390","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jdi.12446","article-title":"Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals","volume":"7","author":"Hirano","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.peptides.2019.170174_bib0395","doi-asserted-by":"crossref","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-\/- mouse model","author":"Gaspari","year":"2013","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.peptides.2019.170174_bib0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2019.170174_bib0405","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2119\/2006-00088.Rac","article-title":"Molecular basis of human CD36 gene mutations","volume":"13","author":"Ra\u0107","year":"2007","journal-title":"Mol. Med. Camb. Mass"},{"key":"10.1016\/j.peptides.2019.170174_bib0410","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0415","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0420","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.peptides.2019.170174_bib0430","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.amjmed.2018.02.023","article-title":"Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE trial","volume":"131","author":"White","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0435","first-page":"109","article-title":"Inflammation as a cardiovascular risk factor","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.peptides.2019.170174_bib0440","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0445","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00100.2012","article-title":"Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes","volume":"304","author":"Timper","year":"2013","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0450","first-page":"16","article-title":"Inflammation and cardiovascular disease: from pathogenesis to therapeutic target","author":"Golia","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.peptides.2019.170174_bib0455","article-title":"Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels","author":"G\u00f3ralska","year":"2017","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2019.170174_bib0460","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/dom.12711","article-title":"Glucose-dependent insulinotropic peptide secretion is induced by inflammatory stimuli in an interleukin-1-dependent manner in mice","volume":"18","author":"Kahles","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0465","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50","author":"Berliner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.peptides.2019.170174_bib0470","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2337\/diab.28.12.1141","article-title":"Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes","volume":"28","author":"Eckel","year":"1979","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0475","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/endo.140.1.6464","article-title":"Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin","volume":"140","author":"McIntosh","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2019.170174_bib0480","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0485","doi-asserted-by":"crossref","first-page":"34139","DOI":"10.1074\/jbc.M704896200","article-title":"Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2019.170174_bib0490","first-page":"578","article-title":"Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase?","volume":"49","author":"Murphy","year":"1995","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.peptides.2019.170174_bib0495","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1172\/JCI110335","article-title":"Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs","volume":"68","author":"Wasada","year":"1981","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2019.170174_bib0500","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11745-011-3650-1","article-title":"Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP","volume":"47","author":"Lu","year":"2012","journal-title":"Lipids"},{"key":"10.1016\/j.peptides.2019.170174_bib0505","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco-and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0510","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1152\/ajpendo.00639.2009","article-title":"On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans","volume":"298","author":"Asmar","year":"2010","journal-title":"AJP Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0515","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jdi.12488","article-title":"Searching for the physiological role of glucose- dependent insulinotropic polypeptide","volume":"7","author":"Juul Holst","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.peptides.2019.170174_bib0520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2019.170174_bib0525","first-page":"10","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","author":"Killion","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0530","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jc.2015-3133","article-title":"Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study","volume":"101","author":"M\u00f8ller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0535","doi-asserted-by":"crossref","first-page":"G1108","DOI":"10.1152\/ajpgi.00282.2014","article-title":"Common variants of GIP are associated with visceral fat accumulation in Japanese adults","volume":"307","author":"Nakayama","year":"2014","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2019.170174_bib0540","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.170174_bib0545","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/XCE.0000000000000093","article-title":"Effects of glucose-dependent insulinotropic polypeptide on glucagon","volume":"5","author":"Christensen","year":"2016","journal-title":"Cardiovasc. Endocrinol."},{"key":"10.1016\/j.peptides.2019.170174_bib0550","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"N\u00f8rregaard","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0555","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00125-015-3618-4","article-title":"GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial","volume":"58","author":"G\u00f6gebakan","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0560","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0565","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.peptides.2019.170174_bib0570","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmet.2017.02.002","article-title":"Monomeric GLP-1 \/ GIP \/ glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice","volume":"6","author":"Jall","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2019.170174_bib0575","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose- dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"826 Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2019.170174_bib0580","article-title":"GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","author":"Gasbjerg","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2019.170174_bib0585","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet Lond. Engl."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978119301524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978119301524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:25:22Z","timestamp":1759310722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978119301524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":117,"alternative-id":["S0196978119301524"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2019.170174","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2019.170174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"170174"}}